Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Université Paris Cité, Centre National De La Recherche Scientifique
InventorsFrédéric PENDINO, Emmanuel DONNADIEU, Mattia FUMAGALLI, Dongjie AN
Estimating the term…
The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA-dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF/CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti-CD19, anti-EGFR, anti-BCMA . . . ) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3). Thus, the present invention relates to an immune cell characterized in that it is defective for RINF.
An immune cell characterized in that it is defective for Retinoid-Inducible Nuclear Factor (RINF).
An ex vivo or in vitro method to obtain improved immune cells that are defective for RINF, comprising:
An ex vivo or in vitro method to obtain CAR-T cells that are defective for RINF comprising the following steps:
(canceled)
(canceled)
Dependencies are inferred from the claim text.